PDCD1 and cancer: In recent years, the rise of immunotherapy has revolutionized the landscape of cancer treatment, especially with the emergence of immune checkpoint inhibitors (ICIs) represented by anti-programmed cell death-1 (anti-PD-1) or anti-programmed cell death ligand-1 (anti-PD-L1).